A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy

Figures & data

Figure 1. Schematic diagrams of the Ad5 vectors and Ad5/F35.

Figure 2. The mechanism of the antitumor effect of vectors incorporating the novel chimeric fiber Ad5/F35 adenovirus. Ad5/F35 first attaches to cells via CD46 or CAR. Once attached, the RGD motif in the penton base interacts with integrin to promote endocytosis and internalization of the adenovirus. Ad5/F35 then lyses the tumor cells via apoptosis. The released adenoviruses infect adjacent tumor cells.

Table 1. Factors influencing the transduction efficacy of Ad5/F35 vectors.

Factors		References
Neutralizing antibodies (nAbs)		^36,^38,^39,
	CD46	^31,^40–43
Receptors	Other receptors	^44,^45
	Integrin (RGD motif)	^46
Insertion of foreign peptides		^47,^20
The affinity to CD46		^51,^52
ECM	Hyaluronidase	^57
	Matrix metalloproteinases (Relaxin)	^64
Factor X (FX)		^67
X-binding protein (X-bp)		^71,^72
	Cell type	^77
Features of cells	Regulation and apoptosis	^79,^80
	The metabolic activity of the host cell	^81
	survival potential	^82

Table 2. Studies using Ad5/F35-based vectors in various cancers.

Ad5/F35 vectors alone		Tumor targeted	Effect compared to Ad5 vectors alone	Studies	References
		Head and neck cancer	Effective	In vitro/in vivo	^83,^84
		Melanoma cells	Effective	In vitro/in vivo	^83
		Glioblastoma	Effective	In vitro/in vivo	^85
		B-lymphocytic Malignancies	Effective	In vitro/in vivo	^86
		Renal cancer cells	Effective	In vitro	^42
Ad5/F35 mediated gene therapy	gene	Tumor targeted	Effect compared to Ad5 mediated genetherapy	Studies	References
	TERT	Head and neck cancer	Enhanced	In vitro/in vivo	^87
	TRAIL	1) Glioblastoma	Enhanced	In vitro/in vivo	^88
		2) Leukemia	Enhanced	In vitro/in vivo	^89
	XAF1	Hepatocellular carcinoma	Enhanced	In vitro/in vivo	^90
	p53	1)Hepatocellular carcinoma	Enhanced	In vitro/in vivo	^91
		2)Breast cancer	Enhanced	In vitro/in vivo	^92
		1) Lung cancer	Enhanced	In vitro	^93
	MKp-E1	2) Mesothelioma	similar	In vitro	^94
			Enhanced/similar	In vitro	^95
			enhanced	in vivo	^95
		3) Bladder cancer	Enhanced	In vitro	^96
		4) Osteosarcoma	Enhanced	In vitro/in vivo	^97
	Hep27	Renal cancer	Enhanced	In vitro/in vivo	^98
Ad5/F35 with chemotherapy	Drugs	Tumor targeted	Effect compared to Ad5 with chemotherapy	Studies	References
Ad5/F35-M/V-HF	DTIC	Melanoma	Enhanced	In vitro/in vivo	^99
Ad5/F35-tk	GCV	Colorectal cancer	Enhanced	In vitro/in vivo	^100
Ad5/F35	Cisplatin	Head and neck cancer	Enhanced	in vivo	^101
Ad5/F35 with radiation	Radiation	Tumor targeted	Effect compared to Ad5 with radiation	Studies	References
Ad5/F35		Head and neck cancer	Enhanced	in vivo	^101
Ad5/F35-APE1 siRNA		Colorectal cancer	Enhanced	In vitro/in vivo	^102

D'Ambrosio E, Del Grosso N, Chicca A, Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. The Journal of hygiene. 1982;89:155–61.

 PubMedGoogle Scholar

Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clinical and diagnostic laboratory immunology. 2004;11:351–7.

 PubMedGoogle Scholar

Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination:efficient human cell infection and bypass of preexisting adenovirus immunity. Journal of virology. 2003;77:8263–71.

 PubMed Web of Science ®Google Scholar

Toivonen R, Koskenvuo J, Merentie M, Soderstrom M, Yla-Herttuala S, Savontaus M. Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5. Virology journal. 2012;9:296.

 PubMed Web of Science ®Google Scholar

Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N, Uzawa K, Tanzawa H, Shimada H, Ochiai T, et al. Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncology reports. 2005;14:831–5.

 PubMed Web of Science ®Google Scholar

Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I, Tagawa M. Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer research. 2007;27:2311–6.

 PubMed Web of Science ®Google Scholar

Shayakhmetov DM, Eberly AM, Li ZY, Lieber A. Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. Journal of virology. 2005;79:1053–61.

 PubMed Web of Science ®Google Scholar

Matsui H, Sakurai F, Kurachi S, Tashiro K, Sugio K, Kawabata K, Yamanishi K, Mizuguchi H. Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene therapy. 2009;16:1050–7.

 PubMed Web of Science ®Google Scholar

Matsui H, Sakurai F, Katayama K, Kurachi S, Tashiro K, Sugio K, Kawabata K, Mizuguchi H. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob. Virus research. 2011;155:48–54.

 PubMed Web of Science ®Google Scholar

Wang H, Liu Y, Li Z, Tuve S, Stone D, Kalyushniy O, Shayakhmetov D, Verlinde CL, Stehle T, McVey J, et al. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. Journal of virology. 2008;82:10567–79.

 PubMed Web of Science ®Google Scholar

Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer research. 2002;62:1063–8.

 PubMed Web of Science ®Google Scholar

Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008;14:3933–41.

 PubMed Web of Science ®Google Scholar

Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, Yun CO, Jooss K. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer research. 2007;67:4399–407.

 PubMed Web of Science ®Google Scholar

Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer gene therapy. 2016;23:229–34.

 PubMed Web of Science ®Google Scholar

Liu Y, Wang H, Yumul R, Gao W, Gambotto A, Morita T, Baker A, Shayakhmetov D, Lieber A. Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Human gene therapy. 2009;20:621–9.

 PubMed Web of Science ®Google Scholar

Greig JA, Buckley SM, Waddington SN, Parker AL, Bhella D, Pink R, Rahim AA, Morita T, Nicklin SA, McVey JH, et al. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Molecular therapy: the journal of the American Society of Gene Therapy. 2009;17:1683–91.

 PubMed Web of Science ®Google Scholar

Drouin M, Cayer MP, Jung D. Adenovirus 5 and chimeric adenovirus 5/F35 employ distinct B-lymphocyte intracellular trafficking routes that are independent of their cognate cell surface receptor. Virology. 2010;401:305–13.

 PubMed Web of Science ®Google Scholar

Thomsen P, Roepstorff K, Stahlhut M, van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Molecular biology of the cell. 2002;13:238–50.

 PubMed Web of Science ®Google Scholar

Tagawa A, Mezzacasa A, Hayer A, Longatti A, Pelkmans L, Helenius A. Assembly and trafficking of caveolar domains in the cell: caveolae as stable, cargo-triggered, vesicular transporters. The Journal of cell biology. 2005;170:769–79.

 PubMed Web of Science ®Google Scholar

Cayer MP, Samson M, Bertrand C, Dumont N, Drouin M, Jung D. Suppression of protein phosphatase 2A activity enhances Ad5/F35 adenovirus transduction efficiency in normal human B lymphocytes and in Raji cells. Journal of immunological methods. 2012;376:113–24.

 PubMed Web of Science ®Google Scholar

Kim SY, Kang S, Song JJ, Kim JH. The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy. International journal of oncology. 2013;42:1337–48.

 PubMed Web of Science ®Google Scholar

Reddy PS, Ganesh S, Yu DC. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006;12:2869–78.

 PubMed Web of Science ®Google Scholar

Suominen E, Toivonen R, Grenman R, Savontaus M. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. The journal of gene medicine. 2006;8:1223–31.

 PubMed Web of Science ®Google Scholar

Hoffmann D, Meyer B, Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. The journal of gene medicine. 2007;9:764–78.

 PubMed Web of Science ®Google Scholar

Wang G, Li G, Liu H, Yang C, Yang X, Jin J, Liu X, Qian Q, Qian W. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. The journal of gene medicine. 2009;11:477–85.

 PubMed Web of Science ®Google Scholar

Acharya B, Terao S, Suzuki T, Naoe M, Hamada K, Mizuguchi H, Gotoh A. Improving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins. Experimental and therapeutic medicine. 2010;1:537–40.

 PubMed Web of Science ®Google Scholar

Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer research. 2007;67:8783–90.

 PubMed Web of Science ®Google Scholar

Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, Qian W. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Molecular cancer therapeutics. 2009;8:1387–97.

 PubMed Web of Science ®Google Scholar

Zhu LM, Shi DM, Dai Q, Cheng XJ, Yao WY, Sun PH, Ding Y, Qiao MM, Wu YL, Jiang SH, et al. Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget. 2014;5:5403–15.

 PubMed Web of Science ®Google Scholar

Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, et al. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer letters. 2011;307:93–103.

 PubMed Web of Science ®Google Scholar

He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, Li L, Wu H, Liu X, Wu M, et al. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Human gene therapy. 2011;22:283–92.

 PubMed Web of Science ®Google Scholar

Fang L, Cheng Q, Liu W, Zhang J, Ge Y, Zhang Q, Li L1, Liu J, Zheng J. Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell. Cancer biology & therapy. 2016;17:664–73.

 PubMed Web of Science ®Google Scholar

Toivonen R, Suominen E, Grenman R, Savontaus M. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer. Oncology reports. 2009;21:165–71.

 PubMed Web of Science ®Google Scholar

Kanno T, Gotoh A, Nakano T, Tagawa M, Nishizaki T. Beneficial oncolytic effect of fiber-substituted conditionally replicating adenovirus on human lung cancer. Anticancer research. 2012;32:4891–5.

 PubMed Web of Science ®Google Scholar

Gotoh A, Kanno T, Nagaya H, Nakano T, Tabata C, Fukuoka K, Tagawa M, Nishizaki T. Gene therapy using adenovirus against malignant mesothelioma. Anticancer research. 2012;32:3743–7.

 PubMed Web of Science ®Google Scholar

Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, Tagawa M, Kasahara N, Kubo S. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer science. 2013;104:1433–9.

 PubMed Web of Science ®Google Scholar

Gotoh A, Nagaya H, Kanno T, Tagawa M, Nishizaki T. Fiber-substituted conditionally replicating adenovirus Ad5F35 induces oncolysis of human bladder cancer cells in in vitro analysis. Urology. 2013;81:920 e7-11.

 PubMed Web of Science ®Google Scholar

Takagi-Kimura M, Yamano T, Tagawa M, Kubo S. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. Cancer gene therapy. 2014;21:126–32.

 PubMed Web of Science ®Google Scholar

Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. The Journal of investigative dermatology. 2008;128:988–98.

 PubMed Web of Science ®Google Scholar

Cho YS, Do MH, Kwon SY, Moon C, Kim K, Lee K, Lee SJ, Hemmi S, Joo YE, Kim MS. Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers. Oncotarget. 2016.

 Google Scholar

Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, VanRoey M, Robinson M, et al. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer. Cancer gene therapy. 2009;16:383–92.

 PubMed Web of Science ®Google Scholar

Xiang DB, Chen ZT, Wang D, Li MX, Xie JY, Zhang YS, Qing Y, Li ZP, Xie J. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer gene therapy. 2008;15:625–35.

 PubMed Web of Science ®Google Scholar